Drug Profile
Research programme: cannabis based therapeutics - One World Cannabis
Alternative Names: Cannabidiol - One World Cannabis; cannabinoid-enriched sublingual disintegrating tablet; Medical cannabis - One World Cannabis; OWC-1808; Tethahydrocannabidiol - One World CannabisLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator One World Cannabis
- Developer One World Cannabis; The Chaim Sheba Medical Center at Tel Hashomer
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Post-traumatic stress disorders
- No development reported Fibromyalgia; Multiple myeloma; Pain
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Fibromyalgia in Israel (Sublingual, Tablet)
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-myeloma in Israel (Sublingual)
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Pain in Israel (Sublingual, Tablet)